Back to Search

CHUNG-JIAH CHEN, MD

MD

Hematology & Oncology Physician

NPI: 1548792377IndividualAccepts Medicare

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

A158441(CA)

CMS Specialties

PrimaryHEMATOLOGY/ONCOLOGY

Education

BAYLOR COLLEGE OF MEDICINE

Class of 2017

Clinical Trials (1)

1
Linked Trials
0
Recruiting
1
With Results

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

NCT00988364COMPLETEDPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (20)

Pro-apoptotic low-density lipoprotein subfractions in type II diabetes.
PMID 17030034·Atherosclerosis·2007
7-preclinical
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
PMID 15383192·Curr Med Res Opin·2004
3-trial
Electronegative low-density lipoprotein.
PMID 15166790·Curr Opin Lipidol·2004
6-review
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
PMID 14757686·Circulation·2004
8-other
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
PMID 12719279·Circulation·2003
3-trial
Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription.
PMID 12695302·Circulation·2003
7-preclinical
Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins.
PMID 12689919·Arterioscler Thromb Vasc Biol·2003
7-preclinical
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients.
PMID 12637336·Arterioscler Thromb Vasc Biol·2003
8-other
Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity.
PMID 11805008·Clin Chem·2002
8-other
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
PMID 11375333·Diabetes·2001
7-preclinical
Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells.
PMID 11031216·Arterioscler Thromb Vasc Biol·2000
4-observational
Microfluidic cell sorter with integrated piezoelectric actuator.
PMID 19649710·Biomed Microdevices·2009
8-other
Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.
PMID 19006286·J Med Chem·2008
7-preclinical
Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine.
PMID 18781943·Curr Med Chem·2008
4-observational
Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.
PMID 18442910·Bioorg Med Chem Lett·2008
7-preclinical
Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
PMID 18417348·Bioorg Med Chem·2008
7-preclinical
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
PMID 18207394·Bioorg Med Chem Lett·2008
8-other
Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
PMID 18032040·Bioorg Med Chem Lett·2008
7-preclinical
Synthesis and characterization of trans-4-(4-chlorophenyl)pyrrolidine-3-carboxamides of piperazinecyclohexanes as ligands for the melanocortin-4 receptor.
PMID 17964151·Bioorg Med Chem Lett·2007
8-other
Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.
PMID 17918824·J Med Chem·2007
4-observational

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 2 locations total

Address
16950 VIA TAZON
SAN DIEGO, CA 92127

Locations (2)

Practice Location

16950 VIA TAZON, SAN DIEGO, CA
(800) 926-8273

Practice Location

200 W ARBOR DR, SAN DIEGO, CA
(800) 926-8273

Quick Facts

NPI
1548792377
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
2
Years in Practice
9
Clinical Trials
1
Publications
20

Are you this provider?

Claim Your Profile